.Pharmacolibrary.Drugs.R_RespiratorySystem.R03C_AdrenergicsForSystemicUse.R03CC02_Salbutamol.Salbutamol

Information

Salbutamol (also known as albuterol) is a short-acting β2 adrenergic receptor agonist used primarily for the relief and prevention of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). It is approved for use as a bronchodilator and is commonly administered via inhalation, but can also be given orally or intravenously in certain scenarios.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.

References

1. Marques, L, & Vale, N (2024). Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients. Pharmaceutics 17(1) –. DOI:10.3390/pharmaceutics17010039 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39861686

2. Tan, WC, & Lee, HS (1991). Pharmacokinetics of oral salbutamol controlled-release in Asian patients with asthma. European journal of clinical pharmacology 41(5) 495–496. DOI:10.1007/BF00626378 PUBMED:https://pubmed.ncbi.nlm.nih.gov/1761082

3. Heuberger, JAAC, et al., & Cohen, AF (2018). Futility of current urine salbutamol doping control. British journal of clinical pharmacology 84(8) 1830–1838. DOI:10.1111/bcp.13619 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29722428

Revisions

• 06/2025 initial generated model